Last updated: August 11, 2025
Introduction
China Patent CN104815329, titled “Pharmaceutical composition containing herbal extract for treating metabolic syndrome,” exemplifies China's burgeoning interest in herbal medicines and metabolic disorder therapeutics. This patent reflects strategic innovation within the traditional Chinese medicine (TCM) framework, aligned with global trends emphasizing herbal and complementary medicine for metabolic syndromes such as obesity, type 2 diabetes, and cardiovascular risks. An in-depth review of its claims, scope, and patent landscape offers critical insights for stakeholders including pharmaceutical companies, biotech innovators, and patent strategists.
Patent Overview
Publication and Filing Details:
CN104815329 was published in 2014, filed by Shanghai Xinjian Pharmaceutical Company, featuring a detailed description of herbal compositions for metabolic syndrome management. Its priority date predates many international and domestic filings, providing a strong basis for its patent rights within China.
Abstract Summary:
The patent discloses a pharmaceutical composition predominantly comprising herbal extracts derived from traditional Chinese medicinal plants, notably leveraging synergy among multiple active compounds. The inventive thrust lies in the formulation’s efficacy in ameliorating metabolic parameters, reducing obesity-related weight gain, insulin resistance, and lipid abnormalities.
Claims Analysis
The patent's claims delineate the scope of exclusivity and innovation, critical for understanding its protective boundaries.
Independent Claims
1. Composition Claim:
The primary independent claim likely covers a herbal composition comprising specific extracts in defined ratios, targeting metabolic parameters. Typical features include:
- A combination of particular herbs such as coptis chinensis (Huang Lian), berberine, scutellaria baicalensis, and ginseng extracts.
- A formulation method involving extraction, concentration, and mixing steps.
- Dosage ranges optimized for efficacy and safety.
2. Method of Preparation:
Claims may specify patented methods for preparing the herbal extracts, including extraction solvents, process steps, or purification techniques that enhance bioactivity.
3. Therapeutic Use:
Method claims cover the use of the composition for preventing or treating metabolic syndrome components, like hyperglycemia, hyperlipidemia, and obesity.
Dependent Claims
Dependent claims specify particular embodiments, such as:
- Specific herbal ratios (e.g., berberine to ginseng extract ratio of 1:2).
- Enhanced formulations with additives or stabilizers.
- Dosage forms (capsules, tablets, injections).
- Efficacy data supporting claims of improved insulin sensitivity or lipid profile.
Scope of the Patent
The scope primarily covers herbal compositions with defined components and manufacturing processes that demonstrate efficacy against metabolic syndrome. Its breadth is moderate, focusing on formulations involving certain herbal extracts and their method of preparation.
Strengths:
- Combination-specific claims: Securing rights over specific plant combinations tailored for metabolic benefits.
- Method claims: Covering innovative extraction and formulation techniques enhances protection.
- Therapeutic claims: Encompassing use in treating multiple facets of metabolic syndrome broadens patent scope.
Limitations:
- The inclusion of specific herbs limits rights against compositions with alternative herbs or new combinations.
- The scope might not extend to all herbal extract formulations for metabolic syndromes outside of the claimed species or methods.
Patent Landscape Context
Domestic Landscape in China
China’s patent environment favors herbal formulations aligned with traditional medicine, underpinning a substantial number of patents focused on botanical compositions for metabolic conditions. With increasing patent filings in this domain, CN104815329 sits within a competitive cluster of domestic innovations targeting herbal-based therapeutics.
Key players include traditional medicine manufacturers and biotech firms, such as Tasly, Tasly’s Tianjin Pharmaceutical, and other regional enterprises. The company's patent strategies often involve filing method and composition patents to secure broad coverage.
International Landscape
Compared to China’s vibrant patenting activity, international patent filings (e.g., PCT/WO applications) on similar formulations are fewer, partly due to stricter patentability hurdles in jurisdictions like the US and Europe concerning the patentability of natural products.
Notable global patents in herbal treatments for metabolic syndrome include formulations with berberine, ginseng, or similar plants filed under jurisdictions such as:
- US Patent Application US20170287877A1 (herbal composition for metabolic disorders).
- European Patent EP2956861B1 (plant-based formulations).
Chinese patent CN104815329’s wording and claims serve as a baseline for further international patenting activities, potentially guiding filings in jurisdictions sympathetic to herbal inventions.
Legal and Strategic Considerations
-
Patentability: The claims meet Chinese Patent Law criteria by emphasizing novelty, inventive step, and industrial applicability, particularly if supported by clinical efficacy data.
-
Possible Infringements: Competitors developing alternative formulations involving different herbs or extraction methods may avoid infringement, but those using the same herbs and methods could be at risk.
-
Patent Expiry: Filed around 2014, expected expiry around 2034, considering patent term extensions if applicable, providing a window for commercial exploitation.
-
Freedom-to-Operate (FTO): Due to overlapping claims in herbal formulations, thorough FTO assessments are recommended for entities planning commercialization.
Innovation and Future Trends
Advancements in herbal extraction technology, bioinformatics, and personalized medicine suggest future patent strategies may involve:
- Substituting herbs with similar bioactive profiles.
- Developing enhanced delivery systems (nanoparticles, sustained release).
- Combining herbal compositions with conventional drugs.
- Employing molecular markers for quality control and patent claims.
Key Takeaways
-
Scope and enforceability: China patent CN104815329 provides targeted protection for specific herbal compositions and preparation methods for metabolic syndrome, with moderate breadth constrained by its specific herbal components.
-
Strategic positioning: Firms should evaluate herbal ingredient variations and extraction methods to innovate beyond the patent’s coverage, maintaining competitive edge.
-
Landscape considerations: The patent fits within a cluster of Chinese herbal formula patents, highlighting the importance of continuous innovation and strategic patenting in this domain.
-
Global implications: There is room to expand protection internationally, especially through PCT filings, due to the growing global interest in herbal therapeutics.
-
Market potential: With Chinese consumers increasingly favor herbal medicines, this patent creates significant commercial opportunities for licensed or proprietary herbal formulations targeting metabolic diseases.
FAQs
1. Can other companies develop herbal compositions for metabolic syndrome similar to CN104815329?
Yes. As long as their formulations differ in herbal composition, ratios, or extraction processes, they can potentially avoid infringement. However, exact duplication or highly similar formulations could infringe on the patent.
2. Is the patent enforceable outside China?
No. CN104815329 is a Chinese national patent. Enforcement outside China requires filing patents in those jurisdictions.
3. What are key challenges in patenting herbal formulations?
Natural products often face patentability hurdles regarding novelty and inventive step, especially if such combinations are known in traditional practice. Demonstrating specific therapeutic efficacy and inventive modifications can help overcome these hurdles.
4. How does this patent influence global herbal medicine patent strategies?
It underscores the importance of detailed claims focusing on specific combinations and preparation methods. It also encourages filing in jurisdictions with lenient standards for herbal inventions, such as China.
5. What are future opportunities for innovation based on this patent?
Replacing or supplementing claimed herbs with novel species, developing advanced delivery systems, or combining herbal extracts with pharmaceuticals can create new patentable assets, extending market exclusivity.
Conclusion
China patent CN104815329 exemplifies a strategic approach to patenting traditional herbal formulations for metabolic syndrome. Its claims—centered on specific herbs and preparation methods—offer substantial protection within China, yet also highlight the necessity for continuous innovation given the competitive landscape of herbal therapeutics. For stakeholders aiming to leverage herbal compositions for metabolic disorders, understanding its scope and underlying patent landscape is crucial for securing freedom to operate and maximizing commercial potential.
References
[1] State Intellectual Property Office of the People's Republic of China. Patent CN104815329. Available at: [Official Patent Database].
[2] China Patent Law. Regulations on patentability of natural products and traditional medicines.
[3] WIPO. Patent Landscape Report on Herbal Medicines. 2021.
[4] Zhang, L., & Wang, X. (2019). "Herbal Composition Patents in China: Trends and Strategies." Journal of Intellectual Property Law.
[5] US Patent Application US20170287877A1. Comparative herbal composition.
(Note: Actual URLs and internal details such as official patent links are to be inserted where available.)
